HEPLISAV-B achieved preliminary quarterly net product revenue of $71M for the fourth quarter of 2024, an increase of 39% compared to $51M for the fourth quarter of 2023. Q4 revenue consensus $71.71M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Questions or Comments about the article? Write to editor@tipranks.com